At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
BI 655130 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IIa, Multicentre, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Treatment With BI 655130 in Adult Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating BI 655130 and Placebo for Dermatitis, Atopic. Completed, enrolled 51 participants across 23 sites in 3 countries.
Detailed Summary
The primary objective of this trial is to investigate the safety, tolerability and efficacy of BI 655130 in patients with Atopic Dermatitis (AD) following repeated intravenous administrations compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
CountriesCanada, Japan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartFeb 2019
Primary CompletionJan 2020
Study CompletionJul 2020
TodayJul 2026
First PostedJan 30, 2019
Enrollment StartFeb 12, 2019
Primary CompletionJan 17, 2020
Study CompletionJul 22, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.4 years ago
Interventions
BI 655130drug
Solution for infusion
Placebodrug
Solution for infusion